Moreover, the application of PD-1 or TIM-3 blockade in CAR-T cell therapy led to an increase in synergistic anti-tumor function, indicating that TIM-3 blockage could be effective in combination with CAR-T therapy [119]. The gene discussed is HAVCR2; the disease is neoplasm.